Evidence map›Paper›PMID 41908667›Full record

ArticleCancer pathogenesis and therapy2026

Low-dose decitabine increases peripheral NKT-like cell proportions in patients with chronic myeloid neoplasms.

Zhanqiang Zhang, Yue Wang, Haojun Zhang, Jinjing Zhao, Zhili Yang, Xiaoqian Wang, Yujie Tang, Xuechun Lu, Rui Xu

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer pathogenesis and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zhanqiang ZhangDepartment of Hematology, Beijing United Family Hospital, Beijing 100015, China.
Yue WangNational Institutes for Food and Drug Control, Beijing 102629, China.
Haojun ZhangSchool of Management, Shanxi Medical University, Taiyuan, Shanxi 030000, China.
Jinjing ZhaoDepartment of Hematology, PLA 305 Hospital, Beijing 100013, China.
Zhili YangDepartment of Hematology, PLA 305 Hospital, Beijing 100013, China.
Xiaoqian WangDepartment of Hematology, PLA 305 Hospital, Beijing 100013, China.
Yujie TangSchool of Management, Shanxi Medical University, Taiyuan, Shanxi 030000, China.
Xuechun LuDepartment of Hematology, The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing 100853, China.
Rui XuDepartment of Hematology, PLA 305 Hospital, Beijing 100013, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Decitabine is widely used in the treatment of chronic myeloid neoplasms, potentially through its immunomodulatory effects on CD8

Indexed as

Low-dose decitabineMyelodysplastic syndromesMyelomonocyticNatural killer T-cellsPrimary myelofibrosis

Identifiers

PMID41908667
PMCPMC13019598

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.